Clinical Trials
3 trialsNCT05208944 2026-05-13
THIO Sequenced With Cemiplimab in Advanced NSCLC
Maia Biotechnology
Phase 2 Active not recruiting
NCT06908304 2026-01-12
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Maia Biotechnology
Phase 3 Recruiting
NCT04646005 2025-09-08
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Regeneron Pharmaceuticals
Phase 2 Completed